Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for TScan Therapeutics (TCRX) over the last 5 years, with Q3 2025 value amounting to $129.8 million.

  • TScan Therapeutics' Shares Outstanding (Diluted Average) rose 938.12% to $129.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.8 million, marking a year-over-year increase of 938.12%. This contributed to the annual value of $112.0 million for FY2024, which is 7071.75% up from last year.
  • Per TScan Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $129.8 million for Q3 2025, which was up 938.12% from $129.7 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Shares Outstanding (Diluted Average) registered a high of $129.8 million during Q3 2025, and its lowest value of $1.4 million during Q2 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $56.4 million (2023), whereas its average is $66.1 million.
  • Per our database at Business Quant, TScan Therapeutics' Shares Outstanding (Diluted Average) soared by 163372.8% in 2022 and then surged by 104.82% in 2023.
  • TScan Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $11.7 million in 2021, then skyrocketed by 106.2% to $24.0 million in 2022, then soared by 172.78% to $65.6 million in 2023, then surged by 70.72% to $112.0 million in 2024, then grew by 15.93% to $129.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $129.8 million for Q3 2025, versus $129.7 million for Q2 2025 and $129.7 million for Q1 2025.